TY - JOUR
T1 - Treatment of dyslipidemia in allogeneic hematopoietic stem cell transplant patients
AU - Marini, Bernard Lawrence
AU - Choi, Sung Won
AU - Byersdorfer, Craig Alan
AU - Cronin, Simon
AU - Frame, David G.
N1 - Publisher Copyright:
© 2015 American Society for Blood and Marrow Transplantation.
PY - 2015/5/1
Y1 - 2015/5/1
N2 - As survival rates in allogeneic hematopoietic stem cell transplantation (HSCT) continue to improve, attention to long-term complications, including cardiovascular disease, becomes a major concern. Cardiovascular diseaseand dyslipidemia are a common, yet often overlooked occurrence post-HSCT that results in significant morbidity and mortality. Also, increasing evidence shows that several anti-hyperlipidemia medications, the 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors in particular, may have a role in modulating graft-versus-host disease (GVHD). However, factors such as drug-drug interactions, adverse effect profiles, and the relative efficacy in lowering cholesterol and triglyceride levels must be taken into account when choosing safe and effective lipid-lowering therapy in this setting. This review seeks to provide guidance to the clinician in the management of dyslipidemia in the allogeneic HSCT population, taking into account the recently published American College of Cardiology/American Heart Association guidelines on hyperlipidemia management, special considerations in this challenging population, and the evidence for each agent's potentialrole in modulating GVHD.
AB - As survival rates in allogeneic hematopoietic stem cell transplantation (HSCT) continue to improve, attention to long-term complications, including cardiovascular disease, becomes a major concern. Cardiovascular diseaseand dyslipidemia are a common, yet often overlooked occurrence post-HSCT that results in significant morbidity and mortality. Also, increasing evidence shows that several anti-hyperlipidemia medications, the 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors in particular, may have a role in modulating graft-versus-host disease (GVHD). However, factors such as drug-drug interactions, adverse effect profiles, and the relative efficacy in lowering cholesterol and triglyceride levels must be taken into account when choosing safe and effective lipid-lowering therapy in this setting. This review seeks to provide guidance to the clinician in the management of dyslipidemia in the allogeneic HSCT population, taking into account the recently published American College of Cardiology/American Heart Association guidelines on hyperlipidemia management, special considerations in this challenging population, and the evidence for each agent's potentialrole in modulating GVHD.
KW - Allogeneic transplantation
KW - Dyslipidemia
KW - Graft-versus-host disease
KW - Late complications
KW - Statins
UR - http://www.scopus.com/inward/record.url?scp=84928209723&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84928209723&partnerID=8YFLogxK
U2 - 10.1016/j.bbmt.2014.10.027
DO - 10.1016/j.bbmt.2014.10.027
M3 - Review article
C2 - 25459644
AN - SCOPUS:84928209723
SN - 1083-8791
VL - 21
SP - 809
EP - 820
JO - Biology of Blood and Marrow Transplantation
JF - Biology of Blood and Marrow Transplantation
IS - 5
ER -